Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press11410.17650/2222-8721-2015-5-2-25-31LECTURES AND REVIEWSЛЕКЦИИ И ОБЗОРЫEfficacy of Actovegin in the treatment of the central and the peripheral nervous systemЭффективность Актовегина при лечении заболеваний центральной и периферической нервной системыBoriskinaL. M.БорискинаЛ. М.
Russian Federation

8 bldg. 2 Trubetskaya St., Moscou, 119991

119991, Москва, ул. Трубецкая, 8, стр. 2

Boriskina.lidiya@gmail.comI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России290620155225312906201529062015Copyright ©; 2015, Boriskina L.M.Copyright ©; 2015, Борискина Л.М.2015Boriskina L.M.Борискина Л.М.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/114

The stimulator of tissue regeneration Actovegin is used in many diseases associated with blood circulation. It’s given to patients with neurological, endocrinological, cardiac and even ophthalmic diseases. Its efficacy is observed in disorders of the brain with the metabolic and vascular nature. It improves the trophism of tissues with injuries, burns and ulcers of the different etiology. It prevents the development of adverse effects as a result of peripheral vascular disorders. Actovegin has received the active application in patients with the long-standing diabetes as a prevention and the treatment of complications, particularly the vascular dementia and the diabetic distal polyneuropathy. The basis for these diseases is the hypoxic nature of the tissue damage. It’s mechanisms direct to the reduction of the influence pathological factors and the recovery of the antioxidant activity of cells.

Стимулятор регенерации тканей Актовегин применяется при многих заболеваниях, связанных с нарушением кровообращения. Препарат назначается пациентам с неврологической, эндокринологической, кардиологической и даже офтальмологической патологией. Эффективность Актовегина отмечена при метаболических и сосудистых нарушениях функции головного мозга. Препарат также улучшает трофику тканей при травмах, ожогах и язвах разной этиологии, предупреждает развитие последствий при периферических сосудистых нарушениях. Актовегин активно используется у пациентов с длительно текущим сахарным диабетом для профилактики и лечения таких осложнений, как сосудистая деменция и периферическая полинейропатия. Механизмы действия препарата связаны со снижением выраженности действия патологических факторов, а также с восстановлением антиоксидантной активности в клетках.

Actovegindiabetes mellitushyperglycemiadistal diabetic polyneuropathysensory neuropathymetabolic neuropathyvascular dementianeuroprotectiontrophic functionАктовегинсахарный диабетгипергликемияпериферическая диабетическая полинейропатиясенсорная нейро- патияметаболическая нейропатиясосудистая деменциянейропротекциятрофическая функция1. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279–99.Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279–99.2. Shaw J.E., Zimmet P.Z., Gries F.A., Ziegler D. Epidemiology of Diabetic Neuropathy. In: Gries F.A., Cameron N.E., Low P.A., Ziegler D. (eds.). Textbook of diabetic neuropathy. Stuttgart / New York: Thieme, 2003. P. 64–82.Shaw J.E., Zimmet P.Z., Gries F.A., Ziegler D. Epidemiology of Diabetic Neuropathy. In: Gries F.A., Cameron N.E., Low P.A., Ziegler D. (eds.). Textbook of diabetic neuropathy. Stuttgart / New York: Thieme, 2003. P. 64–82.3. Dan Ziegler. Современные принципы ведения больных диабетической полинейропатией. Нервно-мышечные болезни 2012;(2):7–19. [Dan Ziegler. Modern principles of monitoring of patients with diabetic polyneuropathy. Nervno-myshechnye bolezni = Neural and Muscular Diseases 2012(2):7–19. (In Russ.)].Dan Ziegler. Современные принципы ведения больных диабетической полинейропатией. Нервно-мышечные болезни 2012;(2):7–19. [Dan Ziegler. Modern principles of monitoring of patients with diabetic polyneuropathy. Nervno-myshechnye bolezni = Neural and Muscular Diseases 2012(2):7–19. (In Russ.)].4. Храмилин В.Н. Диабетическая полинейропатия. Обзор современных рекомендаций. РМЖ. Эндокринология 2012;(32):1580–2. [Khramilin V.N. Diabetic polyneuropathy. Review of modern recommendations. Russkiy medycynskiy zhurnal. Endokrinologiya = Russian Medical Journal. Endocrinology 2012(32):1580–2. (In Russ.)].Храмилин В.Н. Диабетическая полинейропатия. Обзор современных рекомендаций. РМЖ. Эндокринология 2012;(32):1580–2. [Khramilin V.N. Diabetic polyneuropathy. Review of modern recommendations. Russkiy medycynskiy zhurnal. Endokrinologiya = Russian Medical Journal. Endocrinology 2012(32):1580–2. (In Russ.)].5. Abbott C.A., Malik R.A., van Ross E.R. et al. Prevalence and characteristics of painful diabetic neuropathy in a large communitybased diabetic population in the U.K. Diabetes Care 2011;34:2220–4.Abbott C.A., Malik R.A., van Ross E.R. et al. Prevalence and characteristics of painful diabetic neuropathy in a large communitybased diabetic population in the U.K. Diabetes Care 2011;34:2220–4.6. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009;10:393–400.Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009;10:393–400.7. Bulton A., Kempler P., Ametov A., Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes/Metabol Rese and Revi 2013;29:327–33.Bulton A., Kempler P., Ametov A., Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes/Metabol Rese and Revi 2013;29:327–33.8. Kodl C.T., Seaquist E.R. Cognitive dysfunction and diabetes mellitus. Endocri Revi 2008;29(4):494–511. DOI: http://dx.doi.org/10.1210/er.2007-0034.Kodl C.T., Seaquist E.R. Cognitive dysfunction and diabetes mellitus. Endocri Revi 2008;29(4):494–511. DOI: http://dx.doi.org/10.1210/er.2007-0034.9. Чугунова Л.А., Семенова И.В., Орлов Ю.Ю., Шестакова М.В. Сахарный диабет 2 типа и когнитивные нарушения. Сахарный диабет 2008;(1):61–6. [Chugunova L.A., Semenova I.V., Orlov Y.Y., Shestacova M.V. Type 2 diabetes and cognitive impairment. Saharny diabet = Diabetes Mellitus 2008;(1):61–6. (In Russ.)].Чугунова Л.А., Семенова И.В., Орлов Ю.Ю., Шестакова М.В. Сахарный диабет 2 типа и когнитивные нарушения. Сахарный диабет 2008;(1):61–6. [Chugunova L.A., Semenova I.V., Orlov Y.Y., Shestacova M.V. Type 2 diabetes and cognitive impairment. Saharny diabet = Diabetes Mellitus 2008;(1):61–6. (In Russ.)].10. Reske-Nielsen E., Lundbaek K., Rafeisen Q.J. Pathological changes in cerebral and peripheral nervous system of young long-term diabetics. Diabetologia 1965;1: 233–41.Reske-Nielsen E., Lundbaek K., Rafeisen Q.J. Pathological changes in cerebral and peripheral nervous system of young long-term diabetics. Diabetologia 1965;1: 233–41.11. Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999;(16):93–112.Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999;(16):93–112.12. Cox D.J., Kovatchev B.P., GonderFrederick L.A. et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 2005;(28):71–7.Cox D.J., Kovatchev B.P., GonderFrederick L.A. et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 2005;(28):71–7.13. Grodstein F., Chen J., Wilson R.S. et al. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 2001;(24):1060–5.Grodstein F., Chen J., Wilson R.S. et al. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 2001;(24):1060–5.14. Messier C., Awad N., Gagnon M. The relationships between atherosclerosis, heart disease, type 2 diabetes and dementia. Neurol Res 2004;26(5):567–72.Messier C., Awad N., Gagnon M. The relationships between atherosclerosis, heart disease, type 2 diabetes and dementia. Neurol Res 2004;26(5):567–72.15. Korf E.S.C., White L.R., Scheltens P. et.al. Brain aging in very old men with type 2 diabetes the Honolulu-Asia Aging Study // Diabetes Care 2006;29:2268–74.Korf E.S.C., White L.R., Scheltens P. et.al. Brain aging in very old men with type 2 diabetes the Honolulu-Asia Aging Study // Diabetes Care 2006;29:2268–74.16. Schnaider M. Beeri, Goldbourt U., Silverman J.M. et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004;(63):1902–7.Schnaider M. Beeri, Goldbourt U., Silverman J.M. et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004;(63):1902–7.17. Gasparini L., Netzer W.J.,Greengard P., Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 2002;23(6):288–93.Gasparini L., Netzer W.J.,Greengard P., Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 2002;23(6):288–93.18. Leibson C.L., Rocca W.A., Hanson V.A. Risk of dementia amongpersons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997;(145):301–8.Leibson C.L., Rocca W.A., Hanson V.A. Risk of dementia amongpersons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997;(145):301–8.19. Luchsinger J.A., Tang M.X., Stern Y. et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635–41.Luchsinger J.A., Tang M.X., Stern Y. et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635–41.20. Yoshitake Т., Kiyohara Y., Kato I. et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;(45):1161–8.Yoshitake Т., Kiyohara Y., Kato I. et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;(45):1161–8.21. Starr M., Wardlaw J., Ferguson K. et. al. Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. Neurolo Neurosurge Psychiatry 2003;74: 70–6.Starr M., Wardlaw J., Ferguson K. et. al. Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. Neurolo Neurosurge Psychiatry 2003;74: 70–6.22. Antonios N., Siliman S. Diabetes mellitus and stroke. Nort Florida Med 2005;56(2): 17–22.Antonios N., Siliman S. Diabetes mellitus and stroke. Nort Florida Med 2005;56(2): 17–22.23. Harris M.I., Flegal K.M., Cowie C.C. et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1998;21:518–24.Harris M.I., Flegal K.M., Cowie C.C. et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1998;21:518–24.24. Machicao F., Muresanu D.F., Hundsberger H. et al. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. J Neurol Sci 2012;322:222–7.Machicao F., Muresanu D.F., Hundsberger H. et al. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. J Neurol Sci 2012;322:222–7.25. Jansen W., Brueckner G.W. Treatment of chronic cerebrovascular diseases with Actovegin forte. Therapiewoche 1982;41:3–12.Jansen W., Brueckner G.W. Treatment of chronic cerebrovascular diseases with Actovegin forte. Therapiewoche 1982;41:3–12.26. Oswald W.D., Steger W., Oswald B. et al. Increase of fluid cognitive components as an aspect in evaluation drug efficacy. A double-controlled study with Actovegin. ZfPG;4(4):209–20.Oswald W.D., Steger W., Oswald B. et al. Increase of fluid cognitive components as an aspect in evaluation drug efficacy. A double-controlled study with Actovegin. ZfPG;4(4):209–20.27. Semlitsch H.V., Anderer P., Saletu B. Hochmayer I. Topographic mapping of cognitive event-related potentials in a doubleblind, placebo-controlled study with the hemoderivative actovegin in age-associated memory impairment. Neuropsychobiology 1990–91;24:49–56.Semlitsch H.V., Anderer P., Saletu B. Hochmayer I. Topographic mapping of cognitive event-related potentials in a doubleblind, placebo-controlled study with the hemoderivative actovegin in age-associated memory impairment. Neuropsychobiology 1990–91;24:49–56.28. Захаров В.В., Соснина В.Б. Применение антигипоксантов в лечении когнитивных нарушений у больных с сахарным диабетом. Неврологический журнал 2008;5:39–43. [Zakharov V.V., Sosnina V.B. Application of antihypoxants in treatment of cognitive disorders of patients with diabetes mellitus. Nevrologicheskiy zhurnal = Neurological Journal 2008;5:39–43. (In Russ.)].Захаров В.В., Соснина В.Б. Применение антигипоксантов в лечении когнитивных нарушений у больных с сахарным диабетом. Неврологический журнал 2008;5:39–43. [Zakharov V.V., Sosnina V.B. Application of antihypoxants in treatment of cognitive disorders of patients with diabetes mellitus. Nevrologicheskiy zhurnal = Neurological Journal 2008;5:39–43. (In Russ.)].29. Meilin S., Machino F., Elmliger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J Cell Mol Med 2014;18(8):1623–30. doi: 10.1111/jcmm.12297.Meilin S., Machino F., Elmliger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J Cell Mol Med 2014;18(8):1623–30. doi: 10.1111/jcmm.12297.30. Федорович А.А., Рогоза А.Н., Канищева Е.М., Бойцов С.А. Влияние препарата актовегин на метаболическую и вазомоторную функции микрососудистого эндотелия кожи человека. Рациональная фармакотерапия в кардиологии 2010;6(1):53–60. [Fedorovich A.A., Rogoza A.N., Kanishcheva E.M., Boytsov S.A. Effect of the actovegin drug on metabolic and vasomotor function of the human skin microvascular endothelium. Ratsionalnaya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2010;6(1):53–60. (In Russ.)].Федорович А.А., Рогоза А.Н., Канищева Е.М., Бойцов С.А. Влияние препарата актовегин на метаболическую и вазомоторную функции микрососудистого эндотелия кожи человека. Рациональная фармакотерапия в кардиологии 2010;6(1):53–60. [Fedorovich A.A., Rogoza A.N., Kanishcheva E.M., Boytsov S.A. Effect of the actovegin drug on metabolic and vasomotor function of the human skin microvascular endothelium. Ratsionalnaya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2010;6(1):53–60. (In Russ.)].31. Jensen W., Beck E. Treatment of the diabetic polyneuropathy: a controlled double blind study. Med Welt 1987;38:838–41.Jensen W., Beck E. Treatment of the diabetic polyneuropathy: a controlled double blind study. Med Welt 1987;38:838–41.32. Zienger D., Movsesyan L., Mankovsky B. et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32:1479–84. Гурьева И.В., Бегма И.В., Кузина И.В. и др. Патогенетическое лечение Актовегином нейроишемического болевого синдрома в нижних конечностях при сахарном диабете. РМЖ. Эндокринология 2009;17(10):8–11. [Guriyeva I.V., Begma I.V., Kuzina I.V. et al. Pathogenic treatment of neuro-ischemic pain syndrome in lower extremities with Actovegin with diabetes mellitus. Russkiy meditsinskiy zhurnal. Endokrinologiya = Russian Medical Journal. Endocrinology 2009;17(10):8–11. (In Russ.)].Zienger D., Movsesyan L., Mankovsky B. et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32:1479–84. Гурьева И.В., Бегма И.В., Кузина И.В. и др. Патогенетическое лечение Актовегином нейроишемического болевого синдрома в нижних конечностях при сахарном диабете. РМЖ. Эндокринология 2009;17(10):8–11. [Guriyeva I.V., Begma I.V., Kuzina I.V. et al. Pathogenic treatment of neuro-ischemic pain syndrome in lower extremities with Actovegin with diabetes mellitus. Russkiy meditsinskiy zhurnal. Endokrinologiya = Russian Medical Journal. Endocrinology 2009;17(10):8–11. (In Russ.)].